These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32562186)

  • 1. Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?
    Langlois MR; Sniderman AD
    Curr Cardiol Rep; 2020 Jun; 22(8):67. PubMed ID: 32562186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.
    Carr SS; Hooper AJ; Sullivan DR; Burnett JR
    Pathology; 2019 Feb; 51(2):148-154. PubMed ID: 30595507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the Limiting UNdertreatment of lipids in ACS With Rosuvastatin [LUNAR] Trial).
    Ballantyne CM; Pitt B; Loscalzo J; Cain VA; Raichlen JS
    Am J Cardiol; 2013 Feb; 111(4):506-9. PubMed ID: 23237107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines.
    Sathiyakumar V; Park J; Quispe R; Elshazly MB; Michos ED; Banach M; Toth PP; Whelton SP; Blumenthal RS; Jones SR; Martin SS
    Circulation; 2018 Jul; 138(3):244-254. PubMed ID: 29506984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concordance/discordance between serum apolipoprotein B, low density lipoprotein cholesterol and non-high density lipoprotein cholesterol in NATPOL 2011 participants - An epidemiological perspective.
    Solnica B; Sniderman AD; Wyszomirski A; Rutkowski M; Chlebus K; Bandosz P; Pencina MJ; Zdrojewski T
    Int J Cardiol; 2023 Nov; 390():131150. PubMed ID: 37429441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.
    Langlois MR; Chapman MJ; Cobbaert C; Mora S; Remaley AT; Ros E; Watts GF; Borén J; Baum H; Bruckert E; Catapano A; Descamps OS; von Eckardstein A; Kamstrup PR; Kolovou G; Kronenberg F; Langsted A; Pulkki K; Rifai N; Sypniewska G; Wiklund O; Nordestgaard BG;
    Clin Chem; 2018 Jul; 64(7):1006-1033. PubMed ID: 29760220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishing cut-off values for apolipoprotein B and non-HDL-C according to LDL-C values in a South European population.
    Martinez-Hervas S; Real JT; Priego MA; Carratalá A; Sniderman AD; Carmena R; Ascaso JF
    Int J Clin Pract; 2013 Jan; 67(1):81-8. PubMed ID: 23241052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM.
    Langlois MR; Nordestgaard BG; Langsted A; Chapman MJ; Aakre KM; Baum H; Borén J; Bruckert E; Catapano A; Cobbaert C; Collinson P; Descamps OS; Duff CJ; von Eckardstein A; Hammerer-Lercher A; Kamstrup PR; Kolovou G; Kronenberg F; Mora S; Pulkki K; Remaley AT; Rifai N; Ros E; Stankovic S; Stavljenic-Rukavina A; Sypniewska G; Watts GF; Wiklund O; Laitinen P;
    Clin Chem Lab Med; 2020 Mar; 58(4):496-517. PubMed ID: 31855562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein B and non-high-density lipoprotein cholesterol reveal a high atherogenicity in individuals with type 2 diabetes and controlled low-density lipoprotein-cholesterol.
    Fonseca L; Paredes S; Ramos H; Oliveira JC; Palma I
    Lipids Health Dis; 2020 Jun; 19(1):127. PubMed ID: 32505210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention.
    Sniderman AD; Dufresne L; Pencina KM; Bilgic S; Thanassoulis G; Pencina MJ
    Eur Heart J; 2024 Jul; 45(27):2410-2418. PubMed ID: 38700053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What is a good marker for serum cholesterol to identify high-risk patients at general health checks?].
    Fujioka Y
    Rinsho Byori; 2012 Apr; 60(4):328-35. PubMed ID: 22686042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients.
    Johannesen CDL; Mortensen MB; Langsted A; Nordestgaard BG
    J Am Coll Cardiol; 2021 Mar; 77(11):1439-1450. PubMed ID: 33736827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ApoB versus non-HDL-cholesterol: diagnosis and cardiovascular risk management.
    de Nijs T; Sniderman A; de Graaf J
    Crit Rev Clin Lab Sci; 2013 Nov; 50(6):163-71. PubMed ID: 24295059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evidence-based analysis of the National Lipid Association recommendations concerning non-HDL-C and apoB.
    Sniderman AD; Toth PP; Thanassoulis G; Furberg CD
    J Clin Lipidol; 2016; 10(5):1248-58. PubMed ID: 27678443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study.
    Sniderman AD; Islam S; Yusuf S; McQueen MJ
    Atherosclerosis; 2012 Dec; 225(2):444-9. PubMed ID: 23068583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of Total to High-Density Lipoprotein Cholesterol Ratio Discordance With Alternative Lipid Parameters for Coronary Atheroma Progression and Cardiovascular Events.
    Elshazly MB; Nicholls SJ; Nissen SE; St John J; Martin SS; Jones SR; Quispe R; Stegman B; Kapadia SR; Tuzcu EM; Puri R
    Am J Cardiol; 2016 Sep; 118(5):647-55. PubMed ID: 27392507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individual Variation in the Distribution of Apolipoprotein B Levels Across the Spectrum of LDL-C or Non-HDL-C Levels.
    Sayed A; Peterson ED; Virani SS; Sniderman AD; Navar AM
    JAMA Cardiol; 2024 Aug; 9(8):741-747. PubMed ID: 38865115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk.
    Glavinovic T; Thanassoulis G; de Graaf J; Couture P; Hegele RA; Sniderman AD
    J Am Heart Assoc; 2022 Oct; 11(20):e025858. PubMed ID: 36216435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.